Combination immunotherapy for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests two drugs, elranatamab and isatuximab, given together to people whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if the combination can shrink or control the cancer where other therapies have not worked well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has returned or is no longer responding to at least one prior treatment, including an immunomodulatory drug and a proteasome inhibitor.
- You have measurable signs of the disease, such as a blood or urine protein level high enough, an abnormal free light chain ratio, or visible tumors on imaging.
- You are at least 18 years old.
- You have recovered from recent therapy and have adequate kidney, liver, and blood cell counts (specific limits will be checked by the study team).
- You have not had an anti-BCMA bispecific T cell engager before (though other anti-BCMA treatments like CAR-T may be allowed if they weren't the last line of treatment or if you didn't become resistant to them).
- You must agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining radiation therapy with the drug elranatamab can help people with multiple myeloma that has come back or not responded to treatment, especially when the cancer has spread to soft tissues or bones outside the bone marrow. The goal is to see if this combination can make the immune system fight the cancer more effectively.
This trial tests two drugs, mezigdomide (a pill) and elranatamab (an injection), in people whose multiple myeloma has come back or not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This trial tests a new combination of three drugs (belantamab mafodotin, cevostamab, and pomalidomide) for patients with multiple myeloma that has returned or stopped responding to previous treatments. The goal is to see if this combination is safe and effective.
This trial tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to treatment, specifically after they have received a therapy named idecabtagene vicleucel (Abecma). It aims to see if elranatamab can help control the disease.
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) mixed with myeloma cells, given together with a drug called elranatamab. It is for people with multiple myeloma that has not responded to at least three prior treatments.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.